OBJECTIVE: There is substantial evidence that depression constitutes a risk factor for type 2 diabetes mellitus. A recent study has shown that high salivary cortisol levels are associated with decreased insulin sensitivity in unmedicated, depressed patients. Further, antidepressive treatment might have differential effects on hypothalamus-pituitary-adrenal (HPA) system activity. Therefore, the aim of the present study was to examine whether insulin sensitivity improves during anti-depressive treatment in depressed patients with declining HPA system activity. METHOD:Eighty inpatients with an episode of major depressive disorder (DSM-IV criteria) were treated in a double-blind, randomized protocol with either amitriptyline or paroxetine over a period of 5 weeks. After 6 drug-free days, an oral glucose tolerance test was performed on day 1 and again 35 days after antidepressive treatment. For quantification of free cortisol levels, saliva was obtained daily at 8:00 a.m. during weeks -1 (washout) and 5. The study was conducted from May 2005 to December 2005. RESULTS: The insulin sensitivity index(Matsuda) increased in only those patients who remitted from major depressive disorder as a result of treatment with either antidepressant (F = 7.0, df = 1,74; p < .01), while correcting for body mass index. Further, cortisol concentrations declined in remitters and responders to amitriptyline (F = 2.1, df = 1,70; p < .05), but not in any other subgroup. CONCLUSION: Successful antidepressive treatment with either a selective serotonin reuptake inhibitor or a tricyclic substance increases the sensitivity to insulin in nondiabetic depressed patients. The herein presented longitudinal data do not exclude the HPA system as a major contributor to insulin resistance in depressed patients, but underscore the assumption of additional factors.
RCT Entities:
OBJECTIVE: There is substantial evidence that depression constitutes a risk factor for type 2 diabetes mellitus. A recent study has shown that high salivary cortisol levels are associated with decreased insulin sensitivity in unmedicated, depressedpatients. Further, antidepressive treatment might have differential effects on hypothalamus-pituitary-adrenal (HPA) system activity. Therefore, the aim of the present study was to examine whether insulin sensitivity improves during anti-depressive treatment in depressedpatients with declining HPA system activity. METHOD: Eighty inpatients with an episode of major depressive disorder (DSM-IV criteria) were treated in a double-blind, randomized protocol with either amitriptyline or paroxetine over a period of 5 weeks. After 6 drug-free days, an oral glucose tolerance test was performed on day 1 and again 35 days after antidepressive treatment. For quantification of free cortisol levels, saliva was obtained daily at 8:00 a.m. during weeks -1 (washout) and 5. The study was conducted from May 2005 to December 2005. RESULTS: The insulin sensitivity index(Matsuda) increased in only those patients who remitted from major depressive disorder as a result of treatment with either antidepressant (F = 7.0, df = 1,74; p < .01), while correcting for body mass index. Further, cortisol concentrations declined in remitters and responders to amitriptyline (F = 2.1, df = 1,70; p < .05), but not in any other subgroup. CONCLUSION: Successful antidepressive treatment with either a selective serotonin reuptake inhibitor or a tricyclic substance increases the sensitivity to insulin in nondiabetic depressedpatients. The herein presented longitudinal data do not exclude the HPA system as a major contributor to insulin resistance in depressedpatients, but underscore the assumption of additional factors.
Authors: Roland von Känel; Brent T Mausbach; Joel E Dimsdale; Paul J Mills; Thomas L Patterson; Sonia Ancoli-Israel; Michael G Ziegler; Susan K Roepke; Elizabeth A Chattillion; Matthew Allison; Igor Grant Journal: J Am Geriatr Soc Date: 2011-09-21 Impact factor: 5.562
Authors: Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy Journal: CNS Drugs Date: 2010-09 Impact factor: 5.749
Authors: Steven E Arnold; Irwin Lucki; Bethany R Brookshire; Gregory C Carlson; Caroline A Browne; Hala Kazi; Sookhee Bang; Bo-Ran Choi; Yong Chen; Mary F McMullen; Sangwon F Kim Journal: Neurobiol Dis Date: 2014-03-29 Impact factor: 5.996
Authors: Guangliang Wang; Surendra K Rajpurohit; Fabien Delaspre; Steven L Walker; David T White; Alexis Ceasrine; Rejji Kuruvilla; Ruo-Jing Li; Joong S Shim; Jun O Liu; Michael J Parsons; Jeff S Mumm Journal: Elife Date: 2015-07-28 Impact factor: 8.140
Authors: Michael R Fettiplace; Katarzyna Kowal; Richard Ripper; Alexandria Young; Kinga Lis; Israel Rubinstein; Marcelo Bonini; Richard Minshall; Guy Weinberg Journal: Anesthesiology Date: 2016-02 Impact factor: 7.892